Dartmouth-Hitchcock logo
Back
 
Medicine Grand Rounds - SARS-CoV-2/COVID-19, Update on Clinical Care and Therapeutics: A Local Response to a Global Crisis - April 3, 2020

Dr. Zuckerman describes the clinical course for patients with COVID-19, following the predicted course and symptoms of persons with mild disease to those with a severe viral/inflammatory response. He discusses home care, current ED admission criteria, current knowledge base regarding several medications that have a potential positive or negative impact (NSAIDS, ACE inhibitors, statins) as well as the potential for co-infections and the treatment protocol for severely affected patients. He discusses the data available regarding treatment with chloroquine alone or in combination with azithromycin, and the clinical trial of Remdesivir for infected patients. He warns that there is widespread misinformation about efficacy of treatments and caution should be used in reviewing reports of treatment outcomes.

Activity Details

Start Date:  April 3, 2020
End Date:  April 3, 2023

You may claim CME credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Activity Material tab. Click View Presentation to view the recording. View the entire presentation.
  3. Return to this Activity page.
  4. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  5. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

Learning Outcome

Participants will be able to describe the clinical course, supportive care, and treatments for COVID-19, discuss investigational and off-label use of pharmacologic agents in the care of patients with COVID-19, summarize DHMC treatment guidance based on currently available data and share gratitude and appreciation for an incredible community facing a crisis together.

Presenter
  • Richard A. Zuckerman, MD, MPH
    Associate Professor of Medicine
    Geisel School of Medicine at Dartmouth
    Director, Infectious Disease Service for Transplant and Immunocompromised Hosts
    Section of Infectious Disease & International Health
    Dartmouth-Hitchcock Medical Center

    About our presenter:  
    Dr. Richard Zuckerman completed his medical education at Albany Medical Center and both his residency in Internal Medicine and fellowship in Infectious Disease at the University of Washington in Seattle, WA. He earned a Masters of Public Health from the University of Illinois at Chicago. He co-directs and teaches the Geisel pre-clinical courses on Infection Immunity and Inflammation and Medical Microbiology and Immunology. His primary interests are clinical care and research in immune compromised and transplant patients and medical education. Dr. Zuckerman has taken a leadership role in directing therapeutics for COVID-19 at DHMC, and is the institutional primary investigator on trials of the anti-viral agent remdesivir.
Accreditation

Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the online Attestation of Attendance & Evaluation Form (you must register to access).
Disclosure

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. All potential conflict(s) were resolved.


* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio. 

* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion. 


Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center
clpd.support@hitchcock.org


Type:     Internet Activity (Enduring Material)
4 Registered Users

0